Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 (NEST3)

29 juin 2026 mis à jour par: City of Hope Medical Center

A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)

This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make the tumor smaller. Giving neoadjuvant botensilimab and balstilimab may be effective for the treatment of advanced resectable colorectal cancer.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

PRIMARY OBJECTIVE:

I. To estimate the two-year disease-free survival (DFS) rate when treating advanced mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer with botensilimab (BOT)/balstilimab (BAL) followed by surgery.

SECONDARY OBJECTIVES:

I. To determine the major pathologic response rate for patients with advanced mismatch repair proficient or microsatellite stable (pMMR or MSS) colorectal cancer treated with botensilimab (BOT) + balstilimab (BAL) followed by surgery.

II. To evaluate the safety of treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

III. To estimate the pathologic response rate when treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

IV. To estimate the three-year disease-free survival rate when treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

V. To estimate the median recurrence free survival in patients with advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery, among patients who are disease free at the time of surgery.

VI. To describe the proportion of patients that get all four doses of BAL. VII. To describe the quality of life of patients with advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

VIII. To describe the time to surgery after treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

IX. To describe the percent of pMMR/MSS colorectal cancer patients treated with BOT/BAL followed by surgery in which adjuvant therapy is recommended, amount and type received, as well as patient refusal rate.

EXPLORATORY OBJECTIVES:

I. To examine changes in tumor microenvironment in response to BOT/BAL when treating advanced pMMR/MSS colorectal cancer.

II. To explore the serial changes in circulating tumor deoxyribonucleic acid (ctdna) when treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

III. To explore markers on baseline imaging that correlate with response and long-term outcomes.

IV. To determine ctDNA and cell free deoxyribonucleic acid (cfDNA) detectability before, during and after neoadjuvant BOT/BAL and curative-intent surgical resection.

V. To describe the association between detectable ctDNA and cfDNA measured before, during and after neoadjuvant post-neoadjuvant treatment and surgery with DFS and pathologic response.

VI. To describe the difference in time between ctDNA and cfDNA detection (molecular recurrence) and radiographic evidence of disease recurrence following definitive treatment among patients who achieved undetectable ctDNA and/or cfDNA levels after surgery.

VII. Among patients that get presurgical standard of care (SOC) imaging, to describe the presurgical radiologic response.

OUTLINE:

Patients receive botensilimab intravenously (IV), over 30 minutes, on day 1 and balstilimab IV, over 30 minutes, on days 1, 15, 29 and 43 in the absence of disease progression or unacceptable toxicity. 5-16 weeks later, patients then undergo standard of care resection surgery. Patients undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 2 weeks, 4 weeks and every 3 months for 2 years then every 6 months for 1 year.

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Sebastian Perez
  • Numéro de téléphone: 6262184357
  • E-mail: sebperez@coh.org

Lieux d'étude

  • États-Unis
    • Arizona
      • Goodyear, Arizona, États-Unis, 85338
        • Recrutement
        • CTCA at Western Regional Medical Center
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
    • California
      • Corona, California, États-Unis, 92882
        • Recrutement
        • City of Hope Corona
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
      • Duarte, California, États-Unis, 91010
        • Recrutement
        • City of Hope Medical Center
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
      • Huntington Beach, California, États-Unis, 92648
        • Recrutement
        • City of Hope Seacliff
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
      • Irvine, California, États-Unis, 92618
        • Recrutement
        • City of Hope at Irvine Lennar
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
      • Long Beach, California, États-Unis, 90813
        • Recrutement
        • City of Hope at Long Beach Elm
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
      • South Pasadena, California, États-Unis, 91030
        • Recrutement
        • City of Hope South Pasadena
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
      • Upland, California, États-Unis, 91786
        • Recrutement
        • City of Hope Upland
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
    • Georgia
      • Newnan, Georgia, États-Unis, 30265
        • Recrutement
        • City of Hope Atlanta Cancer Center
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Recrutement
        • City of Hope at Illinois Chicago Downtown
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org
      • Zion, Illinois, États-Unis, 60099
        • Recrutement
        • City of Hope at Chicago
        • Chercheur principal:
          • Pashtoon M. Kasi
        • Contact:
          • Pashtoon M. Kasi
          • Numéro de téléphone: 949-671-4673
          • E-mail: kasi@coh.org

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Documented informed consent of the participant and Legally Authorized Representative (when applicable)

    • Assent, when appropriate, will be obtained and documented for adults lacking capacity per institutional guidelines
  • Agreement to allow the use of tissue from past and future surgery and standard of care biopsies
  • Age: ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) ≤ 2
  • Histologically confirmed or cytologically confirmed colorectal adenocarcinoma. Patients with high grade dysplasia on histology plus unequivocal endoscopic or radiological evidence of invasive cancer are eligible.

Patients diagnosed with rectal cancer who will be treated like colon cancer with curative-intent surgery first and no radiation are also eligible, including:

  • Upper rectum or rectosigmoid considered as non-rectal and not undergoing neoadjuvant treatment
  • The tumor component should not extend to less 12 cm from the anal verge.

  • Any patient with rectal cancer for whom radiotherapy is not advised is included in this protocol (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation)

    • Microsatellite stability by mismatch repair by immunohistochemistry, polymerase chain reaction and/or other Clinical Laboratory Improvement Amendments (CLIA) certified next generation sequencing. Only patients with mismatch repair proficient or microsatellite stable (pMMR/MSS) tumors are allowed to enroll in the study
    • Candidate for and planning a curative resection. Must have surgeon identified
    • T4, N+ (American Joint Committee on Cancer [AJCC] TNM staging criteria), or both by central radiographic assessment.

  • Note: Patients with T3N0 stage IIA are excluded. Stage IIB, IIC, IIIA, IIIB, and IIIC are included. Patients with stage IV disease are excluded

    • Absolute neutrophil count (ANC) ≥ 1,500/mm^3
    • Platelets ≥ 75,000/mm^3

  • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment

    • Hemoglobin ≥ 8 g/dL

  • NOTE: Red blood cell transfusions are permitted. Patients should not have active clinically significant bleeding requiring regular transfusions. Iron infusions are also allowed

    • Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease, in which case the liver function tests must meet the other eligibility in the protocol)
    • Aspartate aminotransferase (AST) ≤ 3.0 x ULN
    • Alanine aminotransferase (ALT) ≤ 3.0 x ULN
    • Creatinine clearance of ≥ 40 mL/min per the Cockcroft-Gault formula
    • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
    • Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 9 months for women, and at least 6 months for men, after the last dose of oxaliplatin therapy. If patients discontinue oxaliplatin more than 9 months (females) or 6 months (males) before discontinuation of balstilimab and/or botensilimab, females and males of childbearing potential must use an effective method of birth control or abstain from sexual activity for the course of the study through at least 120 days after the last dose of balstilimab and/or botensilimab.
  • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).
  • The following are acceptable birth control methods for this study: Surgical sterilization (tubal ligation or hysterectomy for women, or vasectomy for men), double-barrier methods (i.e. condoms, diaphragm, cervical cap, or sponge, used together with spermicidal gel or foam), intrauterine device (IUD) (i.e. Progestin, Copper), or hormonal contraceptives (birth control patches, implants, pills, rings, or injections)

Exclusion Criteria:

  • Any treatment for colorectal cancer prior to enrollment that includes (but not limited to) chemotherapy, surgery, radiation, immunotherapy and/or biological therapy.

    • Note: Surgical intervention e.g. a diverting ostomy to relieve an obstruction from colorectal cancer, those patients will be allowed to enter the study as long as no distant metastatic disease
  • Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
  • Prior allogeneic organ transplantation
  • Herbal medications that require a prescription or are anti-cancer
  • Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Please note: patients with more than 1 colorectal cancer tumor at diagnosis (as long as no stage IV disease) are allowed to participate. Pathologic response to each of the tumors will be examined
  • Active acute colonic obstruction. Patients whose obstruction is relieved by a successful defunctioning stoma are allowed once recovered to a fitness level consistent with the other eligibility criteria
  • Clinically significant uncontrolled illness
  • Females only: Pregnant or breastfeeding
  • Prior allergic reaction or hypersensitivity to any of the study drug components
  • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years before starting treatment, i.e., with use of disease-modifying agents or immunosuppressive drugs (excluding hypothyroidism, vitiligo, and psoriasis that is controlled with topical management)
  • History or current evidence of any condition, co-morbidity, therapy, that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
  • Uncontrolled infection with human Immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy (HAART) are eligible. Serological testing for HIV at screening is not required
  • Uncontrolled infection with hepatitis B virus. Patients who are receiving or who have received anti-HBV therapy are eligible. Serological testing for HBV at screening is not required
  • Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Patients on or who have received antiretroviral therapy are eligible. Serological testing for HCV at screening is not required
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Treatment (botensilimab and balstilimab)
Patients receive botensilimab IV, over 30 minutes, on day 1 and balstilimab IV, over 30 minutes, on days 1, 15, 29 and 43 in the absence of disease progression or unacceptable toxicity. 5-16 weeks later, patients then undergo standard of care resection surgery. Patients undergo CT scan and/or MRI and blood sample collection throughout the study.
Procédure: Imagerie par résonance magnétique
Passer une IRM
Autres noms:
  • IRM
  • Résonance magnétique
  • Balayage d'imagerie par résonance magnétique
  • Imagerie Médicale, Résonance Magnétique / Résonance Magnétique Nucléaire
  • M
  • Imagerie IRM
  • Imagerie RMN
  • NMRI
  • Imagerie par résonance magnétique nucléaire
  • Imagerie par résonance magnétique (IRM)
  • IRMs
  • Imagerie par résonance magnétique (procédure)
  • IRM structurelle
Procédure: Collecte d'échantillons biologiques
Subir une collecte d'échantillons de sang
Autres noms:
  • Collecte d'échantillons biologiques
  • Spécimen biologique collecté
  • Collecte de spécimens
Procédure: Tomodensitométrie
Passer un scanner
Autres noms:
  • TDM
  • CHAT
  • Scanner
  • Tomographie axiale informatisée
  • Tomographie assistée par ordinateur
  • Tomodensitométrie
  • tomographie
  • Tomographie axiale informatisée (procédure)
  • Tomodensitométrie (TDM)
  • Scan de chat diagnostique
  • Type de service de scan de chat diagnostique
Biologique: Balstilimab
Étant donné IV
Autres noms:
  • AGEN2034
  • AGEN 2034
  • AGEN-2034
Biologique: Botensilimab
Étant donné IV
Autres noms:
  • AGEN1181
  • AGEN 1181
  • AGEN-1181
  • Anticorps monoclonal anti-CTLA-4 AGEN1181

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Two-year disease-free survival rate
Délai: At 2 years post enrollment
Defined as the percentage of patients that remain free from any signs of colon cancer at two years post-enrollment. Will be compared to the historical control rate of 76.8% (from the FoXTROT adjuvant chemotherapy arm) using a one-sided, one-sample log-rank test.
At 2 years post enrollment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Major pathologic response rate
Délai: Up to 3 years
Defined as the proportion of patients achieving major pathologic responses defined as either a >= 90% tumor reduction or 100% reduction (near complete response + pathologic complete response). Will be compared with the historical control rate of 10% using a one-sided, continuity corrected Z-test.
Up to 3 years
Incidence of adverse events
Délai: Up to 3 years
Assessed according to Common Terminology Criteria for Adverse Events version 6.0. Will be summarized using descriptive statistics.
Up to 3 years
Pathologic response rate
Délai: Up to 3 years
Defined as the proportion of patients achieving a pathologic response, defined as a ≥ 50% tumor reduction.
Up to 3 years
Three-year disease-free survival rate
Délai: At 3 years post-enrollment
Defined as the percentage of patients that remain free from any signs of colon cancer at three years post-enrollment. Will be summarized similar to 2-year survival but at the 3-year mark.
At 3 years post-enrollment
Recurrence free survival
Délai: Time from surgery to date of first cancer recurrence or death as a result of any cause, whichever occurs first, up to 3 years
Assessed among patients that are disease free at the time of surgery. Will be graphically represented using Kaplan-Meier methods and summarized using descriptive statistics.
Time from surgery to date of first cancer recurrence or death as a result of any cause, whichever occurs first, up to 3 years
Number of patients who get all four doses of balstilimab divided by number of enrolled patients
Délai: Up to 3 months
Will be summarized using descriptive statistics.
Up to 3 months
Change in Eastern Cooperative Oncology Group
Délai: Up to 3 years
Will be summarized using descriptive statistics.
Up to 3 years
Time to surgery
Délai: Up to 9 months
Will be summarized using descriptive statistics.
Up to 9 months
Proportion of patients in which adjuvant therapy is recommended, of these the percent who refuse adjuvant therapy
Délai: Up to 9 months
Will be summarized using descriptive statistics.
Up to 9 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

City of Hope Medical Center

Collaborateurs

National Cancer Institute (NCI)

Les enquêteurs

  • Chercheur principal: Pashtoon M Kasi, City of Hope Medical Center

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

27 décembre 2026

Achèvement primaire (Estimé)

27 mai 2027

Achèvement de l'étude (Estimé)

27 mai 2027

Dates d'inscription aux études

Première soumission

5 mai 2026

Première soumission répondant aux critères de contrôle qualité

12 mai 2026

Première publication (Réel)

19 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 25964 (Autre identifiant: City of Hope Medical Center)
  • P30CA033572 (Subvention/contrat des NIH des États-Unis)
  • NCI-2026-02923 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner